VCYT VERACYTE, INC.companySEC Filings & Insider Trading Activity 2026
Latest VERACYTE, INC. (VCYT) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 26, 2026, a 10-Q quarterly report filed on November 5, 2025, an 8-K current report filed on March 16, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for VERACYTE, INC. (VCYT) (SEC CIK 1384101), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: development and commercialization of genomic and molecular diagnostic tests for oncology and other indications
- • Emphasis on regulatory adaptations for IVDR/UKNI in Northern Ireland, and new Swiss IvDO aligning with IVDR from 2022
Risk Factors
- • Regulatory risk from Protecting Access to Medicare Act of 2014 (PAMA) may reduce test reimbursement rates, negatively impacting revenues and margins
- • Geopolitical risk from Middle East conflicts potentially disrupting Israel business and employees acquired in C2i Acquisition
Management Discussion & Analysis
- • Revenue not explicitly stated; net income $66.4M in 2025 vs $24.1M in 2024, showing significant profitability improvement
- • Operating margin details not provided; net income growth from $24.1M (2024) to $66.4M (2025) indicates margin improvement
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New risk: Impact of 2025 US federal government shutdown on operations and macroeconomic volatility, including currency fluctuations and regional conflicts (Russia-Ukraine, Israel)
- • Updated risk: Restructuring and deconsolidation of Veracyte SAS in August 2025 causing $20.5M impairment and decline in biopharmaceutical revenue by 74% YoY Q3
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • New C-suite role: Dr. Kevin Haas (age 40) appointed Chief Development and Technology Officer, effective March 24, 2026
- • Recruited from Myriad Genetics (MYGN) where he served as CTO since 2021, bringing deep genomics/bioinformatics expertise directly relevant to VCYT's diagnostic platform
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings released Feb 25, 2026 — full results in Exhibit 99.1
- • Filing is "furnished" not "filed" — limits legal liability, standard for earnings releases
Annual Reports Archive10-K
AI-powered analysis of VERACYTE, INC. (VCYT) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of VERACYTE, INC. (VCYT) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of VERACYTE, INC. (VCYT) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | — | $361.1M | $445.8M | $517.1M |
| Gross Profit | — | $229.7M | $298.1M | $362.5M |
| Operating Income | -$41.1M | -$85.8M | $16.1M | $57.8M |
| Net Income | -$36.6M | -$74.4M | $24.1M | $66.4M |
| Gross Margin | — | 63.6% | 66.9% | 70.1% |
| Op. Margin | — | -23.8% | 3.6% | 11.2% |
| Net Margin | — | -20.6% | 5.4% | 12.8% |
| Balance Sheet | ||||
| Total Assets | — | $1.1B | $1.3B | $1.4B |
| Equity | — | $1.0B | $1.2B | $1.3B |
| ROE | — | -7.1% | 2.1% | 5.1% |
Source: XBRL financial data from VERACYTE, INC. (VCYT) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 16, 2026 | — | Analysis | — |
10-K | Feb 26, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 25, 2026 | — | Analysis | — |
8-K | Jan 12, 2026 | — | — | |
10-Q | Nov 5, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Feb 28, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 7, 2024 | Jun 30, 2024 | — | |
10-Q | May 8, 2024 | Mar 31, 2024 | — | |
10-K | Feb 29, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 8, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 9, 2023 | Jun 30, 2023 | — | |
10-Q | May 5, 2023 | Mar 31, 2023 | — | |
10-K | Mar 1, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 3, 2022 | Jun 30, 2022 | — | |
10-Q | May 4, 2022 | Mar 31, 2022 | — | |
10-K | Feb 28, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 9, 2021 | Sep 30, 2021 | — | |
10-Q | Jul 29, 2021 | Jun 30, 2021 | — | |
10-Q | May 10, 2021 | Mar 31, 2021 | — | |
10-K | Feb 22, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 2, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest VCYT SEC filings in 2026?
VERACYTE, INC. (VCYT) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on March 16, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did VCYT file its most recent 10-K annual report?
VERACYTE, INC. (VCYT) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view VCYT 10-Q quarterly reports?
VERACYTE, INC. (VCYT)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every VCYT 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has VCYT filed recently?
VERACYTE, INC. (VCYT)'s most recent 8-K was filed on March 16, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find VCYT insider trading activity (Form 4)?
SignalX aggregates every VCYT Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does VCYT file with the SEC?
VERACYTE, INC. (VCYT) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new VCYT filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for VERACYTE, INC. (VCYT).
What is VCYT's SEC CIK number?
VERACYTE, INC. (VCYT)'s SEC CIK (Central Index Key) number is 1384101. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1384101 to look up all VCYT filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find VCYT return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from VERACYTE, INC. (VCYT) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of VERACYTE, INC. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 50+ filings.